Polaris Group (TPE:6550)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
19.90
-0.40 (-1.97%)
Apr 2, 2026, 1:30 PM CST
Market Cap17.11B -51.0%
Revenue (ttm)40.60M -62.1%
Net Income-3.93B
EPS-5.10
Shares Out859.89M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,120,126
Average Volume1,939,402
Open20.15
Previous Close20.30
Day's Range19.80 - 20.80
52-Week Range18.55 - 46.50
Beta0.82
RSI33.93
Earnings DateMay 14, 2026

About Polaris Group

Polaris Group, together with its subsidiaries, offers biotechnology, drug testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It develops ADI-PEG 20 for the treatment of various cancer indications, as well as provides healthcare consulting, staffing, and MDS solutions. The company was incorporated in 2006 and is based in Grand Cayman, Grand Cayman. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 165
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6550
Full Company Profile

Financial Performance

In 2025, Polaris Group's revenue was 40.60 million, a decrease of -62.05% compared to the previous year's 107.00 million. Losses were -3.93 billion, 56.9% more than in 2024.

Financial Statements